Alimera Sciences

249 articles with Alimera Sciences

• Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress

  9/23/2020

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN ® (fluocinolone acetonide intravitreal implant) 0.19mg will be featured in over 20 papers and presentations during the EURETINA 2020 Virtual Congress, to be held on October 2-4, 2020. Key presentations include data supporting the

• Alimera Sciences Signs Distribution Agreement With Medis Pharmaceutical to Commercialize Iluvien® in Austria and the Czech Republic

  9/15/2020

  Medis will enable immediate access of ILUVIEN to patients in Austria, and will manage reimbursement negotiations for ILUVIEN in the Czech Republic

• UPDATE -- Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020

  9/9/2020

  Alimera Sciences, Inc., a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that Rick Eiswirth, President and Chief Executive Officer, will present a corporate overview at the H. C. Wainwright and Company 22nd Annual Global Virtual Investor Conference on Tuesday September 15, 2020 at 3:30 PM ET.

• Alimera Sciences Announces Participation at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 15, 2020

  9/9/2020

  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, today announces that Rick Eiswirth, President and Chief Executive Officer, will present a corporate overview at the  H. C. Wainwright and Company 22nd Annual Global Virtual Investor Conference

• Alimera Sciences Obtains Reimbursement Approval for ILUVIEN® Use in Non-Infectious Posterior Uveitis in Scotland

  9/8/2020

  Continued execution on strategy to grow international sales of ILUVIEN with new territory approvals, expanded reimbursement of posterior uveitis, and further market penetration

• Alimera Sciences Announces Enrollment of First Patient in Landmark NEW DAY Clinical Trial to Evaluate ILUVIEN® as Baseline Therapy for Diabetic Macular Edema

  9/1/2020

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces that it has enrolled the first patient in the company’s NEW DAY clinical trial, a randomized, controlled, multi-center study designed to generate prospective data for ILUVIEN®

• Alimera Sciences Announces National Reimbursement Granted for ILUVIEN® in the NetherlandsILUVIEN receives pricing and reimbursement approvals for both diabetic macular edema and posterior uveitis indications simultaneously

  8/26/2020

  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary received an add-on status for the pricing and reimbursement approval for ILUVIEN ® in the Netherlands from the Ministry of Health, effective September 1, 2020. Pricing and reimbursement approv

• Alimera Sciences to Present at the LD Micro 500 Virtual Conference on September 2, 2020

  8/25/2020

  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, today announces that Rick Eiswirth, President and Chief Executive Officer, will give a virtual corporate presentation at the LD Micro 500 taking place online on Wednesday, September 2, 2020 at 1:00 PM ET followed by a live Q&A session with registered investors and other conf

• Alimera Sciences Signs Distribution Agreement With Nordic Prime to Expand International Sales of ILUVIEN® Into Nordic Countries

  8/13/2020

  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, today announced that its Ireland-based European subsidiary, Alimera Sciences Europe Limited, has signed a distribution agreement with Nordic Prime ApS to serve as Alimera’s distribution partner in Denmark, Finland, Norway and Sweden for ILUVIEN ® 190 micrograms intravitreal imp

• Alimera Sciences Announces Second Quarter 2020 Financial Results and Provides Corporate Update

  7/29/2020

  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces financial results for the three months ended June 30, 2020.

• Alimera Sciences to Report Second Quarter 2020 Financial Results on Wednesday, July 29, 2020 and Provide Corporate UpdateConference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time

  7/22/2020

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will report second quarter 2020 financial results on Wednesday, July 29, 2020 after the market close. Management will host a conference call at 9:00 AM ET on Thursday, July 30, 2020, to review financial results and provide an update on corporate developme

• Alimera Sciences Initiates Landmark NEW DAY Clinical Trial to Evaluate ILUVIEN® as Baseline Therapy for Diabetic Macular Edema

  7/9/2020

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced the initiation of the company’s NEW DAY clinical trial, a randomized, controlled, multi-center study designed to generate prospective data for ILUVIEN

• Alimera to Present at the June 2020 Virtual Summer Investor SummitCorporate presentation and live webcast scheduled for June 9, 2020 at 3:55 pm ET

  6/3/2020

  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that Rick Eiswirth, Alimera’s President and Chief Executive Officer will give a corporate presentation at the June 2020 Virtual Summer Investor Summit taking place online from June 9- 12, 2020. The presentation will be held on Tuesday, June 9, 2020 at 3:55

• Alimera Sciences Announces First Quarter 2020 Financial Results and Provides Corporate Update

  4/29/2020

  Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces financial results for the three months ended March 31, 2020.

• Alimera Sciences to Report First Quarter 2020 Financial Results on Wednesday, April 29, 2020 and Provide Corporate UpdateConference Call to be held Thursday, April 30, 2020 at 9:00am Eastern Time

  4/24/2020

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will report first quarter 2020 financial results on Wednesday, April 29, 2020 after the market close. Management will host a conference call at 9:00 AM ET on Thursday, April 30, 2020, to review financial results and provide an update on corporate develop

• Alimera Sciences Receives $1.8 Million Loan Under the Paycheck Protection Act

  4/23/2020

  Alimera Sciences, Inc. announces it received on April 22, 2020 approximately $1.8 million in support from the federal government under the Paycheck Protection Program.

• Alimera Sciences Pre-Announces Expected Top Line Revenue for Q1 2020 and Provides COVID-19 Business Update

  4/13/2020

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announces top-line revenue guidance for the quarter ended March 31, 2020. Alimera expects to report consolidated net revenue for the first quarter of 2020 exceeding $14 million, which compares to $12.9 million in the first qu

• Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement

  3/31/2020

  Alimera Sciences, Inc., a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has appointed Steven T. Gill as Vice President, Thought Leader Engagement.

• Alimera Sciences Data Available for the 11th Annual Congress on Controversies in Ophthalmology: Europe Virtual Conference

  3/25/2020

  Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that nine posters on ILUVIEN ® (fluocinolone acetonide intravitreal implant) 0.19 mg for intravitreal injection will be available online during and after the 11 th Annual Congress on Controversies in Ophthalmology (COPHy) conference beginnin

• Alimera Sciences Reports Record Fourth Quarter and 2019 Results

  2/26/2020

  Alimera Sciences, Inc., a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announced financial results for the three months and year ended December 31, 2019.